Coronavirus Disease 2019 Myocarditis: Insights into Pathophysiology and Management

Mahmoud Abdelnabi; Nouran Eshak; Yehia Saleh; Abdallah Almaghraby

doi:10.15420/ecr.2020.16

Coronavirus Disease 2019 Myocarditis: Insights into Pathophysiology and Management

Eur Cardiol. 2020 Jun 17:15:e51. doi: 10.15420/ecr.2020.16. eCollection 2020 Feb.

Authors

Mahmoud Abdelnabi¹, Nouran Eshak^{2

3}, Yehia Saleh^{4

5}, Abdallah Almaghraby⁴

Affiliations

¹ Cardiology and Angiology Unit, Department of Clinical and Experimental Internal Medicine, Medical Research Institute, Alexandria University Alexandria, Egypt.
² Rheumatology Unit, Department of Internal Medicine, Faculty of Medicine, Alexandria University Alexandria, Egypt.
³ Department of Internal Medicine, Texas Tech University, Health Science Center Lubbock, TX, US.
⁴ Department of Cardiology, Faculty of Medicine, Alexandria University Alexandria, Egypt.
⁵ Department of Internal Medicine, Michigan State University East Lansing, MI, US.

Abstract

The world is dealing with a global pandemic of severe acute respiratory coronavirus 2 (SARS-CoV-2). Coronavirus disease 2019 (COVID-19), which is the illness caused by SARS-CoV-2, is overwhelming healthcare systems around the world. Although the main clinical manifestations of COVID-19 are respiratory symptoms, several reports have noted myocarditis, cardiomyopathy, arrhythmias and cardiac arrests as COVID-19 complications. Here, the authors highlight the current understanding of the pathophysiology of myocarditis related to COVID-19 and its management.

Keywords: COVID-19; cytokine storm; immunomodulation; myocarditis.

Publication types

Review